Physician profile
Oscar Benavides
NPI 1356493977
$5,216.40
in general payments reported to CMS, 2019-2025
20 companies · $337 in 2025
The $337 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $978 · 2020: $698 · 2021: $996 · 2022: $723 · 2023: $839 · 2024: $645 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,821.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,182.44 | 2019-2025 | Airsupra, Farxiga, Lokelma |
| Abbvie INC. | $574.94 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Amarin Pharma, INC. | $436.13 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $387.43 | 2019-2023 | Steglatro, Segluromet, Steglujan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $383.66 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $378.16 | 2020-2024 | Mounjaro, Jardiance, Emgality |
| Smith+Nephew, INC. | $321.45 | 2020-2025 | Grafix Pl, Grafix, Stravix Pl |
| Amgen INC. | $217.89 | 2021-2024 | Repatha, Otezla, Evenity |
| Eisai INC. | $206.60 | 2021 | |
| Janssen Pharmaceuticals, INC | $181.35 | 2019 | |
| Novo Nordisk INC | $152.90 | 2019-2024 | Rybelsus, Ozempic |
| Allergan, INC. | $128.80 | 2019-2020 | |
| Radius Health, INC. | $122.22 | 2019 | |
| Vanda Pharmaceuticals INC. | $106.50 | 2024 | Fanapt |
| Agios Pharmaceuticals, INC. | $98.83 | 2024 | Pyrukynd |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $81.60 | 2023 | |
| Averitas Pharma INC. | $70.00 | 2023 | Qutenza |
| Axsome Therapeutics, INC. | $64.55 | 2024 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.44 | 2023 | Relistor |
| Novartis Pharmaceuticals Corporation | $58.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oscar Benavides listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.